Log in

NASDAQ:SGMOSangamo Therapeutics Stock Price, Forecast & News

+0.06 (+0.52 %)
(As of 08/5/2020 04:00 PM ET)
Today's Range
Now: $11.50
50-Day Range
MA: $10.23
52-Week Range
Now: $11.50
Volume1.11 million shs
Average Volume1.60 million shs
Market Capitalization$1.62 billion
P/E RatioN/A
Dividend YieldN/A
Sangamo Therapeutics, Inc. focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation. Its therapeutic products which are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; SB-FIX for the treatment of hemophilia B; ST-400 for the treatment of beta-thalassemia; and SB-318 for the treatment of Mucopolysaccharidosis Type I and SB-913 for the treatment of Mucopolysaccharidosis Type II, which are lysosomal storage disorders (LSDs). The company also develops ST-920, a gene therapy for fabry disease. It has collaboration and license agreements with Kite Pharma, Inc., Pfizer Inc., Bioverativ Inc., and Shire International GmbH, as well as license partnerships with Dow AgroSciences LLC, Sigma-Aldrich Corporation, Genentech, Inc., Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Read More
Sangamo Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.98 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:SGMO



Sales & Book Value

Annual Sales$102.43 million
Book Value$3.73 per share


Net Income$-95,190,000.00


Market Cap$1.62 billion
Next Earnings DateN/A
+0.06 (+0.52 %)
(As of 08/5/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SGMO News and Ratings via Email

Sign-up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions

How has Sangamo Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Sangamo Therapeutics' stock was trading at $7.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SGMO shares have increased by 63.8% and is now trading at $11.50.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Sangamo Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Sangamo Therapeutics

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics Inc (NASDAQ:SGMO) issued its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.41 by $0.67. Sangamo Therapeutics had a negative return on equity of 22.68% and a negative net margin of 89.31%.
View Sangamo Therapeutics' earnings history

What price target have analysts set for SGMO?

4 brokerages have issued 1 year target prices for Sangamo Therapeutics' shares. Their forecasts range from $11.00 to $14.00. On average, they expect Sangamo Therapeutics' stock price to reach $12.50 in the next year. This suggests a possible upside of 8.7% from the stock's current price.
View analysts' price targets for Sangamo Therapeutics

Has Sangamo Therapeutics been receiving favorable news coverage?

Media headlines about SGMO stock have trended negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sangamo Therapeutics earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future.
View the latest news about Sangamo Therapeutics

Who are some of Sangamo Therapeutics' key competitors?

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD), Micron Technology (MU), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Alibaba Group (BABA), Editas Medicine (EDIT) and Intel (INTC).

Who are Sangamo Therapeutics' key executives?

Sangamo Therapeutics' management team includes the following people:
  • Dr. Alexander D. Macrae, CEO, Pres & Director (Age 56)
  • Ms. Kathy Y. Yi, EVP, CFO, Principal Accounting Officer & Sec. (Age 47)
  • Dr. Edward R. Conner, Sr. VP & Chief Medical Officer (Age 46)
  • Dr. Edward Rebar, Sr. VP & CTO
  • Mr. McDavid Stilwell, VP of Corp. Communications & Investor Relations

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

Who are Sangamo Therapeutics' major shareholders?

Sangamo Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.48%), Candriam Luxembourg S.C.A. (0.26%), Swiss National Bank (0.18%), Frontier Capital Management Co. LLC (0.16%), DAVENPORT & Co LLC (0.11%) and UBS Group AG (0.11%). Company insiders that own Sangamo Therapeutics stock include Edward R Conner, H Stewart Parker, Joseph S Zakrzewski, Kathy Yi and Stephen George Dilly.
View institutional ownership trends for Sangamo Therapeutics

Which institutional investors are selling Sangamo Therapeutics stock?

SGMO stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Candriam Luxembourg S.C.A., Creative Planning, DAVENPORT & Co LLC, Rhenman & Partners Asset Management AB, Frontier Capital Management Co. LLC, Dupont Capital Management Corp, and Edge Wealth Management LLC.
View insider buying and selling activity for Sangamo Therapeutics

Which institutional investors are buying Sangamo Therapeutics stock?

SGMO stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, WINTON GROUP Ltd, Russell Investments Group Ltd., Swiss National Bank, Vanguard Capital Wealth Advisors, Diversified Trust Co, Raymond James Financial Services Advisors Inc., and ProShare Advisors LLC. Company insiders that have bought Sangamo Therapeutics stock in the last two years include H Stewart Parker, and Joseph S Zakrzewski.
View insider buying and selling activity for Sangamo Therapeutics

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sangamo Therapeutics' stock price today?

One share of SGMO stock can currently be purchased for approximately $11.50.

How big of a company is Sangamo Therapeutics?

Sangamo Therapeutics has a market capitalization of $1.62 billion and generates $102.43 million in revenue each year. The biopharmaceutical company earns $-95,190,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. Sangamo Therapeutics employs 302 workers across the globe.

What is Sangamo Therapeutics' official website?

The official website for Sangamo Therapeutics is www.sangamo.com.

How can I contact Sangamo Therapeutics?

Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.